Fnu Vikash, MD, M.Med1, Carlos Figueredo, MD2, Vikash Kumar, MD3, Thomas Ullman, MD2 1Albert Einstein College of Medicine, New York, NY; 2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; 3Creighton University School of Medicine, Brooklyn, NY
Introduction: Ulcerative colitis (UC) poses a significant challenge as a chronic inflammatory condition affecting the colon. Etrolizumab, a monoclonal antibody targeting the β7 integrin subunit, has emerged as a potential solution for both inducing and maintaining remission in UC patients. This meta-analysis seeks to comprehensively assess the efficacy of etrolizumab in both phases of UC treatment induction and maintenance, with primary outcomes being clinical remission rates.
Methods: A thorough systematic review, spanning from 2010 to 2024, was conducted across reputable databases such as PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials. Out of 28 studies, only double-blind, placebo-controlled trials investigating etrolizumab's efficacy in UC management were considered for inclusion. The criteria included adults with moderate to severe UC treated with Etrolizumab versus placebo. Data on clinical remission rates were carefully extracted and analyzed utilizing random-effects models.
Results: The analysis revealed a significant increase in the likelihood of achieving clinical remission during the induction phase with etrolizumab (pooled odds ratio [OR]: 3.25, 95% confidence interval [CI]: 1.10–9.65, p < 0.03) and a trend towards improvement in the maintenance phase (pooled OR: 1.43, 95% CI: 0.91–2.23, p < 0.12). These findings suggest substantial potential for Etrolizumab to improve outcomes by reducing mucosal inflammation and promoting sustained remission.
Discussion: Etrolizumab demonstrates substantial efficacy in inducing remission in patients with moderate to severe UC, positioning it as a promising option for initial treatment. While further investigation is needed to confirm its role in maintaining remission, etrolizumab could enhance UC management, especially for patients who have not responded to conventional therapies. Future studies must assess its long-term efficacy and compare its effectiveness with other biological agents.
Figure: Results
Disclosures:
Fnu Vikash indicated no relevant financial relationships.
Carlos Figueredo indicated no relevant financial relationships.
Vikash Kumar indicated no relevant financial relationships.
Thomas Ullman: BMS – Consultant. Pfizer – Advisor or Review Panel Member, Grant/Research Support.
Fnu Vikash, MD, M.Med1, Carlos Figueredo, MD2, Vikash Kumar, MD3, Thomas Ullman, MD2. P4305 - Efficacy of Etrolizumab in Inducing and Maintaining Remission in Ulcerative Colitis: A Comprehensive Meta-Analysis, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
